SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
about
Cinnamic Acid and Its Derivatives: Mechanisms for Prevention and Management of Diabetes and Its Complications.Special considerations for the treatment of chronic kidney disease in the elderly.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy.Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.SGLT2 Inhibitors: Benefit/Risk Balance.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.A Case of Septic Shock Due to Serratia marcescens Pyelonephritis and Bacteremia in a Patient Receiving Empagliflozin.Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.[L'acidocétose euglycémique dans le diabète de type 2 traité avec un inhibiteur du cotransporteur sodium-glucose de type 2].High glucose-mediated overexpression of ICAM-1 in human vaginal epithelial cells increases adhesion of Candida albicans.Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.Pharmacological management of type 2 diabetes: what's new in 2017?Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential.Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan.Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
P2860
Q37673273-E55E2C2B-57A8-463D-A988-4AC0900B0347Q38737061-E14555E6-63B6-422A-9A8A-0C4ED6146B1FQ38783203-C2EFDAA1-547B-4A4E-9284-D27AA22E0BFAQ38807217-08F86C94-AAAB-4CD5-8DD6-FCCDCDF8B09CQ38856808-C334CF45-55CC-4477-ACE9-BAFF14239706Q38902321-561355E0-16F0-4A57-AD38-2FDB5908454AQ38906041-996F330C-4B45-4FCE-AEAF-B823E0B80F37Q38931842-31D027CE-A79B-4AA9-99B5-711ECEC9E82BQ39063447-15BE569E-7D17-4BE9-96FA-6B97F2C22548Q40439768-E2C5E7C2-B6C5-429D-93DD-5489F413676BQ41092635-76E55859-B538-4C62-9135-E5514D9775EFQ41092793-1E9DE06E-2687-4E34-9F0E-651340284878Q41997111-DF30BDE5-D0AF-42A5-BD0D-CE0984CF0522Q47293312-E23D6636-8234-4243-8318-8569995ED923Q47687852-038530B7-A2BF-47E4-B48F-AD4909F2BC2FQ47696671-D30F7F02-BDC3-43E3-9117-25CA88C80118Q47726421-58DDBA81-28DF-46A1-BBCC-214B650CBF7CQ48112714-462DB57C-CC90-4D7E-8064-91EFFA876E7FQ50100476-4F8615C1-EE33-47EC-965D-CE222C71BA9EQ55053753-AC835CFA-F6C8-42A6-9DF6-AF8F1103CCAA
P2860
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
@en
type
label
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
@en
prefLabel
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
@en
P2860
P1476
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
@en
P2093
André J Scheen
P2860
P304
P356
10.1517/14740338.2015.1100167
P407
P577
2015-10-29T00:00:00Z